international immunopharmacology

[1] The suppressive effect of dabrafenib, a therapeutic agent for metastatic melanoma, in IgE-mediated allergic inflammation.

[2] cutaneous langerhans cell histiocytosis with gastrointestinal involvement treated with dabrafenib

[3] Identification of targetable BRAF ΔN486_P490 variant by whole genome sequencing leading to dabrafenib-induced remission of a BRAF-mutant pancreatic adenocarcinoma.

[4] The suppressive effect of dabrafenib, a therapeutic agent for metastatic melanoma, in IgE-mediated allergic inflammation.

[5] Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma.

[6] mir-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating adam9 and vegf-a

[7] dabrafenib in combination with trametinib in the treatment of patients with braf v600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience

[8] cutaneous langerhans cell histiocytosis with gastrointestinal involvement treated with dabrafenib